Endo Appoints New CMO
This article was originally published in Scrip
Endo International Plc has named Craig Paterson chief medical officer. Paterson will be responsible for the company's global clinical development strategies and lifecycle management. Before joining Endo, Paterson was senior vice-president of medical and clinical development for Salix Pharmaceuticals and he has held roles within medical and clinical development at GlaxoSmithKline plc and King Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.